Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.38 USD
Change Today -0.011 / -2.82%
Volume 93.9K
CPHI On Other Exchanges
Symbol
Exchange
Berlin
NYSE Amex
As of 8:04 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

china pharma holdings inc (CPHI) Snapshot

Open
$0.40
Previous Close
$0.39
Day High
$0.40
Day Low
$0.38
52 Week High
02/20/15 - $0.56
52 Week Low
10/23/14 - $0.21
Market Cap
16.5M
Average Volume 10 Days
102.2K
EPS TTM
$-0.57
Shares Outstanding
43.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA PHARMA HOLDINGS INC (CPHI)

Related News

No related news articles were found.

china pharma holdings inc (CPHI) Related Businessweek News

No Related Businessweek News Found

china pharma holdings inc (CPHI) Details

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. It offers products in the form of dry powder injectibles, liquid injectibles, tablets, capsules, oral solutions, and granules. The company’s products are used for the treatment of central nervous system and cerebral-cardiovascular, anti-infection and respiratory, and digestive and other diseases. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and surgery-thrombus deep phlebitis; and Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and lipoprotein blood diseases. The company also provides Bumetanide to treat edema diseases; candesartan for hypertension; Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor Dispersible tablets for tympanitis, lower respiratory tract infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and lipoprotein blood diseases; and Clarithromycin granules and capsules for nasopharynx, respiratory tract, and skin tissue infections. In addition, it offers Naproxen Sodium and Pseudophedrine Hydrochloride Sustained Release tablets to relieve cold, sinus, and flu symptoms; Gull Wood extract syrup; Hepatocyte growth-promoting factor; Tiopronin; compound ammonium glycyrrhetate s; Omeprazole; Vitamin B6; and Granisetron Hydrochloride injection, as well as Recombined Human Fibroblast Growth Factor products for the repair of wounded skin cells. The company distributes its products through independent regional distributors. China Pharma Holdings, Inc. is based in Haikou, the People’s Republic of China.

397 Employees
Last Reported Date: 03/30/15

china pharma holdings inc (CPHI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $225.6K
Compensation as of Fiscal Year 2014.

china pharma holdings inc (CPHI) Key Developments

China Pharma Holdings, Inc. Announces Consolidated Financial Results for the Year Ended December 31, 2014; Provides Tax Rate Guidance for the Year Ending December 31, 2015 and 2016

China Pharma Holdings, Inc. announced consolidated financial results for the year ended December 31, 2014. For the full year, the company’s revenues for the year ended December 31, 2014 were $24,927,707, a decrease of 24% from revenues of $32,806,678 for the year ended December 31, 2013. This decrease primarily resulted from decreases in sales throughout all its product categories, especially the company’s CNS Cerebral &Cardio Vascular products (decreased by approximately $2,800,000) and the company’s Anti-Viro/Infectious & Respiratory products (decreased by approximately $1,800,000). Loss from operations was $25,254,268 in 2014 compared to loss from operations of $18,606,397 in 2013. The main reasons for the increase in loss were lower revenue and higher bad debt expenses in 2014. Loss before income taxes was $25,970,333 against $18,946,636 a year ago. Net loss for the year 2014 was $26,047,375, or $0.60 per basic and diluted share, compared to net loss of $20,008,049, or $0.46 per basic and diluted share for the year 2013. The decrease in net income was mainly due to the decrease in revenue, increase in bad debt expense, and losses from natural disaster. Net cash provided by operating activities was $4,572,372 against $8,595,815 a year ago. Purchases of property and equipment were $5,128,699 against $18,794,261 a year ago. Advances for purchases of intangible assets were $714,697 against $298,631 a year ago. For the year ending December 31, 2015 and 2016, the company renewed its ‘National High-Tech Enterprise’ status from the PRC government in the third quarter of 2013. With this designation, for the years ending December 31, 2015 and 2016, the company will continue to a preferential tax rate of 15% which is notably lower than the statutory income tax rate of 25%.

China Pharma Holdings, Inc., 2014 Earnings Call, Mar 31, 2015

China Pharma Holdings, Inc., 2014 Earnings Call, Mar 31, 2015

China Pharma Holdings, Inc., Annual General Meeting, Dec 29, 2014

China Pharma Holdings, Inc., Annual General Meeting, Dec 29, 2014., at 21:00 China Standard Time. Location: Conference Room, 2nd Floor, Jiahai Building. Agenda: To elect three independent director nominees to Board of Directors to serve until the next annual meeting and until their successors are elected and qualified; and to transact such other business as may properly come before the Annual Meeting or any adjournment thereof.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPHI:US $0.38 USD -0.011

CPHI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPHI.
View Industry Companies
 

Industry Analysis

CPHI

Industry Average

Valuation CPHI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.7x
Price/Book 0.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA PHARMA HOLDINGS INC, please visit www.chinapharmaholdings.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.